Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series

Abstract

Background. We report our experience with vinorelbine, a widely used chemotherapeutic, in unselected metastatic breast cancer patients treated in clinical routine. Patients and Methods. The data of all patients with metastatic breast cancer receiving vinorelbine with or without trastuzumab during a six year period were reviewed. Patients received vinorelbine intravenous 25–30 mg/m2 or 60–80 mg/m2 orally in days 1 and 8 of a 21 day cycle. Results. Eighty-seven women were included. Sixty-two patients received vinorelbine alone and 25 patients received vinorelbine in combination with trastuzumab. In 67 patients this was the first line treatment for metastatic disease and in 20 patients it was 2nd or later line of treatment. The median TTP was six months (range: 1–45). The median overall survival was 11.5 months (range: 1–83). Seventy patients were evaluable for response. In patients receiving first line treatment 44.4% had a response while in the second and subsequent lines setting 12.5% of patients responded (P = 0.001). Objective response was obtained in 63.6% of patients receiving concomitant trastuzumab and in 25% of patients receiving vinorelbine alone (P = 0.0002). Conclusion. This study confirms a high disease control rate. Response rate and TTP were superior in first line treatment compared to subsequent lines.

A Systematic Review and Pooled Analysis of Studies of Oral Etoposide in Metastatic Breast Cancer

“…For example a recent analysis of retrospective series of eribulin in pretreated metastatic breast cancer has disclosed a RR of 20%, a CBR of 46%, a pooled PFS OF 3.8 months and OS of 9.7 months, all very similar with the respective results for oral etoposide (23). In our series of metastatic breast cancer patients treated with vinorelbine in the first or later line setting, RR was 37% overall but only 12% as a second or later line treatment (24). The median TTP was six months for the whole series independently of line of treatment.…”

<p>Co-delivery of everolimus and vinorelbine via a tumor-targeted liposomal formulation inhibits tumor growth and metastasis in RCC</p>

“…Additionally, it was effective in impeding metastasis in advanced stage breast cancer patients 60. A combination of vinorelbine and trastuzumab was shown to be significantly more effective for the treatment of metastatic breast cancer compared to the monotherapy 61. Nonetheless, vinorelbine has been shown to have some side effects including neutropenia, peripheral neuropathy and gastrointestinal (GI) complications 60…”

Distinct characterization of two vinorelbine-resistant breast cancer cell lines developed by different strategies

“…In clinical treatment, patients received vinorelbine intravenous 25-30 or 60-80 mg/m 2 orally in days 1 and 8 of a 21-day cycle (30)(31)(32), which was similar to the way we developed BC-TS cells. As discussed above, BC-TS shows lower migratory behavior and resistant ability compared to the conventional continuous exposure strategy developed in breast cancer BC-DS cells.…”